**Name of Journal:** *World* *Journal* *of* *Meta-Analysis*

**Manuscript NO:** 70877

**Manuscript Type:** META-ANALYSIS

**Efficacy and safety of fingolimod in stroke: A systemic review and meta-analysis**

Zhao K *et* *al*. Fingolimod for treating stroke

Kai Zhao, Yu Guo, Ming-Fei Yang, Qiang Zhang

**Kai Zhao, Yu Guo,** Graduate School, Qinghai University, Xining 810016, Qinghai Province, China

**Ming-Fei Yang, Qiang Zhang,** Department of Neurosurgery, Qinghai Provincial People's Hospital, Xining 810007, Qinghai Province, China

**Author contributions:** Zhang Q and Zhao K conceived the idea and designed the study; Zhao K and Guo Y screened the studies and extracted the data independently; Yang MF and Guo Y analysed and interpreted the data; Zhao K and Guo Y wrote the first draft of the manuscript; Zhang Q proofread the manuscript before submission; all authors reviewed the manuscript and approved the final version.

**Supported by** the National Key R&D Program of China, No. 2018YFC1312601; and the Project of Science and Technology Department of Qinghai Province, No. 2020-ZJ-774.

**Corresponding author: Qiang Zhang, MD, PhD, Chief Doctor, Surgeon,** Department of Neurosurgery, Qinghai Provincial People's Hospital, No. 2 Gonghe Road, Xining 810007, Qinghai Province, China. zhangqiang691212@163.com

**Received:** August 18, 2021

**Revised:** November 13, 2021

**Accepted:** December 24, 2021

**Published online:** December 28, 2021

**Abstract**

BACKGROUND

Brain tissue injury in stroke patients involves inflammation around the infarction lesion or hematoma, which is an important reason for disease deterioration and can result in a poor prognosis. The meta-analysis of animal experiments has concluded that fingolimod could treat stroke in animal models by effectively reducing lymphocyte infiltration. However, no evidence-based efficacy and safety evaluation of fingolimod in stroke patients is currently available.

AIM

To determine whether fingolimod could promote reduction of infarction lesion or hematoma and improve neurological prognosis in stroke patients.

METHODS

Data extracted for treatment effect included count of T-lymphocytes with cluster of differentiation 8 expression (CD8+ T cells, × 106/mL), lesion volume (infarction or hematoma, mL), and modified Barthel indexes. Data extracted for safety was risk ratio (RR). Overall standard mean difference (SMD) with its 95% confidence interval (95%CI) and pooled effect with its 95%CI were calculated with a fixed-effects model. *I*-square (*I*2) was used to test the heterogeneity. Funnel plot symmetry and Egger's regression were used to evaluate publication bias.

RESULTS

Four high-quality randomized controlled trials were included. There was a significant difference in CD8+ T cell count (*I*2 = 0, overall SMD = -3.59, 95%CI: -4.37-2.80, *P* = 0.737) and modified Barthel index (*I*2 = 0, overall SMD = 2.42, 95%CI: 1.63-3.21, *P* = 0.290) between the fingolimod and control groups. However, there was no significant difference in lesion volume (*I*2 = 10.6%, overall SMD = -0.17, 95%CI: -0.75-0.42, *P* = 0.917), fever (pooled RR = 0.93, 95%CI: 0.97-2.32, *P* = 0.864), suspected lung infection (pooled RR = 0.90, 95%CI: 0.33-2.43, *P* = 0.876), or any adverse events occurring at least once (pooled RR = 0.82, 95%CI: 0.36-1.87, *P* = 0.995) between the fingolimod and control groups. There was no publication bias. All of the results were stable as revealed by sensitivity analysis.

CONCLUSION

Fingolimod improves neurological function in stroke patients without promotion of lesion absorption. Taking fingolimod orally (0.5 mg/d, 3 consecutive days) is safe except for patients with rare severe adverse events.

**Key Words:** Acute ischemic stroke; Intracerebral hemorrhage; Fingolimod; Meta-analysis; Treatment

**©The** **Author(s) 2021.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Zhao K, Guo Y, Yang MF, Zhang Q. Efficacy and safety of fingolimod in stroke: A systemic review and meta-analysis. *World* *J* *Meta-Anal* 2021; 9(6): 585-597

**URL:** <https://www.wjgnet.com/2308-3840/full/v9/i6/585.htm>

**DOI:** https://dx.doi.org/10.13105/wjma.v9.i6.585

**Core Tip:** Brain tissue injury in stroke patients involves inflammation around the infarction lesion or hematoma, which is an important reason for disease deterioration and can result in a poor prognosis. Our systemic review and meta-analysis of recent randomized controlled trials found that fingolimod might improve neurological function in stroke patients by reducing lymphocyte infiltration in the brain effectively; however, we did not find the evidence that fingolimod could promote infarction lesion or hematoma absorption. In general, oral fingolimod (0.5 mg/d, 3 consecutive days) was safe in stroke patients except for some rare severe adverse events.

**INTRODUCTION**

Stroke, which mainly consists of acute ischemic stroke (AIS) with cerebral infarction and hemorrhagic stroke with intracerebral hematoma (ICH), is a common neurological disease with a high mortality and disability rate. Especially, during the coronavirus disease 2019 pandemic, related coagulopathy might be associated with ischemic stroke, cerebral hemorrhage, and cerebral venous thrombosis, which aggravated the financial burden in the world[1,2]. For severe stroke patients whose condition has deteriorated rapidly, surgical intervention should be performed, which is considered the best way to save lives[3]. Thus, to reduce the risk of disease deterioration and promote the recovery of nervous system function, it is important to perform timely intervention at the early stage of stroke.

Fingolimod is a newly approved drug for the treatment of multiple sclerosis. It can be metabolized to the active metabolite of fingolimod phosphate *via* sphingosine kinase. Fingolimod phosphate has a high affinity for sphingosine-1-phosphate receptors 1, 3, 4, and 5[4]. Sphingosine-1-phosphate and its receptors can regulate lymphocyte migration *via* upstream cell signaling pathways. Thus, fingolimod phosphate can block the ability of lymphocytes to enter or exit the lymph nodes, which can reduce the number of lymphocytes in peripheral blood[5]. Although fingolimod can be used for the treatment of multiple sclerosis with unknown mechanism, its role as an immunomodulator might involve the reduction of the migration of lymphocytes to central nervous system[6].

Brain tissue injury in stroke patients involves inflammation around the infarction lesion or hematoma, which is an important reason for disease deterioration and can result in a poor prognosis[7]. The meta-analysis of animal experiments has concluded that fingolimod could treat stroke in animal models by effectively reducing lymphocyte infiltration[8]. However, evidence-based efficacy and safety evaluation of fingolimod in stroke patients is currently not available. We hypothesized that fingolimod could effectively and safely promote reduction of infarction lesion or hematoma and improve neurological prognosis in AIS or ICH patients by reducing lymphocyte infiltration. In this study, we performed a systemic review and meta-analysis of recent randomized controlled trials (RCTs) to confirm this hypothesis.

**MATERIALS AND METHODS**

***Protocol*** ***used***

This systemic review and meta-analysis were performed referring to the protocol published in the database of International Platform of Registered Systematic Review and Meta-analysis Protocols (INPLASY, https://[inplasy.c](http://inplasy.com/)om/).

***Literature*** ***search***

A literature search was performed in the three public electronic databases: PubMed, Embase, and Cochrane. The strategy of literature search in PubMed was as follows: ("Fingolimod Hydrochloride"[Mesh]) OR (((((2-Amino-2-(2-(4-octylphenyl)ethyl)-1,3-propanediol hydrochloride[Title/Abstract]) OR (FTY?720[Title/Abstract])) OR (Gilenya[Title/Abstract])) OR (Gilenia[Title/Abstract])) OR (Fingolimod[Title/Abstract])) AND (("Stroke"[Mesh]) OR (((((((((((((((((Stroke\*[Title/Abstract]) OR (Cerebrovascular Accident\*[Title/Abstract])) OR (CVA\* [Title/Abstract])) OR (Cerebrovascular Apoplexy[Title/Abstract])) OR (Apoplexy, Cerebrovascular[Title/Abstract])) OR (Vascular Accident, Brain[Title/Abstract])) OR (Brain Vascular Accident\*[Title/Abstract])) OR (Vascular Accidents, Brain[Title/Abstract])) OR (Cerebrovascular Stroke\*[Title/Abstract])) OR (Stroke\*, Cerebrovascular[Title/Abstract])) OR (Apoplexy[Title/Abstract])) OR (Cerebral Stroke\*[Title/Abstract])) OR (Stroke\*, Cerebral[Title/Abstract])) OR (Stroke\*, Acute[Title/Abstract])) OR (Acute Stroke\*[Title/Abstract])) OR (Cerebrovascular Accident\*, Acute[Title/Abstract])) OR (Acute Cerebrovascular Accident\*[Title/Abstract]))). The strategy of literature search in Embase was as follows: (exp Stroke or Stroke$:ab,ti or 'Cerebrovascular Accident$':ab,ti or CVA$:ab,ti or 'Cerebrovascular Apoplexy':ab,ti or 'Apoplexy, Cerebrovascular':ab,ti or 'Vascular Accident, Brain':ab,ti or 'Brain Vascular Accident$':ab,ti or 'Vascular Accidents, Brain':ab,ti or 'Cerebrovascular Stroke$':ab,ti or 'Stroke$, Cerebrovascular':ab,ti or Apoplexy:ab,ti or 'Cerebral Stroke$':ab,ti or 'Stroke$, Cerebral':ab,ti or 'Stroke$, Acute':ab,ti or 'Acute Stroke$':ab,ti or 'Cerebrovascular Accident$, Acute':ab,ti or 'Acute Cerebrovascular Accident$':ab,ti) or (exp 'Cerebral Hemorrhage' or 'Hemorrhage$, Cerebrum':ab,ti or 'Cerebrum Hemorrhage$':ab,ti or 'Cerebral Parenchymal Hemorrhage$':ab,ti or 'Hemorrhage$, Cerebral Parenchymal':ab,ti or 'Parenchymal Hemorrhage$, Cerebral':ab,ti or 'Intracerebral Hemorrhage$':ab,ti or 'Hemorrhage$, Intracerebral':ab,ti or 'Hemorrhage$, Cerebral':ab,ti or 'Cerebral Hemorrhage$':ab,ti or 'Brain Hemorrhage$, Cerebral':ab,ti or 'Cerebral Brain Hemorrhage$':ab,ti or 'Hemorrhage$, Cerebral Brain':ab,ti).

***Study*** ***selection***

The articles involving the efficacy and safety of fingolimod in the treatment of stroke patients were screened. The inclusion criteria were: (1) Language and regions were not restricted; (2) Date of publication was up to December 31, 2020; (3) RCTs; (4) Patients suffered from AIS or ICH and the onset time was less than 6 h; (5) Fingolimod was used as the clinical intervention and the basic treatment methods were standard treatment according to the current American Heart Association guidelines; and (6) Outcomes involved assessment of immune cells, lesion volume, neurological function, and adverse events. The exclusion criteria were: (1) Duplicated publications; (2) Reviews, comments, letters, case reports, protocols of clinical trials, and conference papers; (3) Animal experiments; and (4) Articles with data irrelevant to this meta-analysis.

***Data*** ***extraction***

In consideration of the pharmacological action of fingolimod, absolute immunological cell counts (× 106/mL) in blood might be the most intuitive index. Especially, T-lymphocytes with cluster of differentiation 8 expression (CD8+ T cells) play a key role in damaging the nervous system due to its cell killing effect, which could result in inflammatory edema[9]. The edema around the infarction or hematoma could result in serious neurologic impairment in stroke patients[10,11]. Thus, a rapid reduction of absolute infarction or hematoma volume might be the key of treatment in stroke patients. Lesion volume (mL) was defined as absolute infarction volume in AIS patients or absolute hematoma in ICH patients. The National Institute of Health stroke scale (NIHSS) is the specialized assessment to measure recovery of neurological function[12]. The Modified Barthel index (mBI) is one of the earliest and the most commonly used methods for assessing ADL (activity of daily living) in rehabilitation medicine, which has high validity and reliability in assessment of stroke[13]. Although risk ratio (RR) is often used as an effect size in cohort studies, it might be significant to assess the probability of adverse events like the number of patients to be harmed in clinical trials[14]. In this study, the data extracted included CD8+ T cell count, lesion volume (infarction or hematoma), NIHSS, mBI, and RR of safety. The data at time points near baseline, which might reflect condition of stroke at early treatment, were extracted. In addition, some confounders, which might result in errors, were adjusted, including characteristics of participation, period of treatment, and other factors. If the original data could not be acquired, other data were also extracted such as the difference between data at baseline and those at other time point.

***Risk*** ***of*** ***bias***

The quality assessment of included articles was performed *via* the Cochrane Collaboration’s Tool of Assessing Risk of Bias using Review Manager 5.3 before data extraction.

***Statistical*** ***analysis***

We made the definition that the counts of studies selected or those with data extracted were positive events (+). The others were negative events (-). Kappa was calculated to test the agreement between Kai Zhao and Yu Guo. Kappa > 0.6 meant a high agreement. Zhang Q would make the final decision. Continuous variables with a normal distribution are expressed as the mean ± SD. Statistical difference of data before treatment in the intervention and control groups was tested by one-way analysis of variance (ANOVA) using SigmaStat version 4.0. If there was no statistical difference, data after treatment were directly used for meta-analysis. Relative numbers and their 95% confidence intervals (95%CI) are used to describe count data. Meta-analysis was performed using corresponding modules in [Software for Statistics and Data Science](https://www.baidu.com/Link?url=JO_VfQvdNezgmFpahMSJqPq1rrkgSWYh7fG32UNbwwO&wd=&eqid=8fe32cd600547d23000000035eb85504) (Stata, version 15.1; College Station, Texas 77845, United States). The overall standard mean difference (SMD) with its 95%CI and pooled effect with its 95%CI were calculated with a fixed-effects model. *I*-square (*I*2) was used to test the heterogeneity. Sensitivity analysis was performed to evaluate the stability of overall results by recalculating the overall SMD or pooled effect of the remaining studies after omitting the study with the highest quality or the fixed-effects model was switched to a random-effects model. Funnel plot symmetry and Egger's regression were used to evaluate publication bias. The methods to reduce heterogeneity and enhance sensitivity were the deletion of studies with publication bias or studies with the lowest quality and subgroup analysis. All *P* values were two-sided with a significant level at 0.05.

**RESULTS**

***Study*** ***selection*** ***and*** ***characteristics***

Totally, 185 articles were retrieved from three databases according to the strategy. After screening according to the inclusion and exclusion criteria, four articles[15-18] reporting RCTs were enrolled ultimately (Figure 1). The Kappa of agreement of studies included by Kai Zhao and Yu Guo was 0.601 (*P* < 0.001; Table 1). One study emphasized the changes of inflammatory factors in patients with ICH after taking fingolimod orally[19]. One study emphasized the role of rehabilitation nursing in AIS patients after taking fingolimod orally[20]. The assessment of article quality *via* Cochrane Collaboration’s Tool of Assessing Risk of Bias is shown in Figure 2. Three studies (Ying Fu *et* *al*[15], Ying Fu *et* *al*[16], and Zilong Zhu *et* *al*[17]) were evaluated as having insignificant risk bias in allocation concealment except for low risk in one study (De-Cai Tian *et* *al*[18]). There was no bias in performance, detection, attrition, or reporting. Other risk biases were insignificant in all studies. The articles finally included were published in 2014 to 2018 (Table 2). There were 67 stroke patients, including 56 AIS patients and 11 ICH patients, whose age ranged from 49 to 74 years. The period of oral fingolimod were 3 consecutive days after hospitalization. The oral dose was 0.5 mg/d. Conclusion with the same tendency was that fingolimod could effectively and safely treat AIS or ICH.

***Meta-analysis***

Due to that some data were expressed *via* only one figure, some original data could not be acquired directly, which may result in missing of some data. The Kappa of agreement of data extraction between Zhao K and Guo Y was 0.634 (*P* < 0.001; Table 3). To acquire a more accurate result of meta-analysis, we tested the statistical difference of CD8+ T cell counts at baseline and 1 day after taking fingolimod orally, lesion volume at baseline and 7 d after taking fingolimod orally, and mBI scores at baseline and 90 d after taking fingolimod orally between studies *via* ANOVA. Unfortunately, there were significant statistical differences (*P* < 0.05) in all of continuous variables. Finally, we calculated difference between data at different time points manually to perform meta-analysis (Table 4). RRs and their 95%CIs of different adverse events, which consisted of fever, suspected lung infection, all adverse events occurring at least once, and other serious events involving hemorrhage of the digestive tract, cerebral hernia, bradycardia, atrial flutter, and thrombocytopenia, were calculated directly by referring to the count of adverse events occurring in patients of the fingolimod groups and control groups. Since no patients developed bradycardia, atrial flutter, or thrombocytopenia in the control groups, RRs of these adverse events were not calculated (Table 5).

Analysis with a fixed-effects model showed that there was no heterogeneity (*I*2 = 0, Figure 3) in the two studies used for comparing overall SMD difference in CD8+ T cell counts and lesion volume except for two articles used for comparing overall SMD difference in mBI scores (*I*2 = 10.6%, Figure 3). There was a significant difference in CD8+ T cell counts (overall SMD = -3.59, 95%CI: -4.37--2.80, *P* = 0.737, Figure 3) and mBI (overall SMD = 2.42, 95%CI: 1.63-3.21, *P* = 0.290, Figure 3) between the fingolimod and control groups. However, there was no significant difference in lesion volume between the fingolimod and control groups (overall SMD = -0.17, 95%CI: -0.75-0.42, *P* = 0.917, Figure 3). Pooled RRs and their 95%CIs were calculated with a fixed-effects model. The RRs of fever (*I*2 = 0, pooled RR = 0.93, 95%CI: 0.97-2.32, *P* = 0.864, Figure 4), suspected lung infection (*I*2 = 0, pooled RR = 0.90, 95%CI: 0.33-2.43, *P* = 0.876, Figure 4), and all adverse events occurring at least once (*I*2 = 0, pooled RR = 0.82, 95%CI: 0.36-1.87, *P* = 0.995, Figure 4) showed no significant difference between the fingolimod and control groups. Meta-analysis was not performed in RRs of other serious events because there was only one study reporting hemorrhage of the digestive tract or cerebral hernia and RRs of bradycardia, atrial flutter, and thrombocytopenia could not be calculated.

***Publication*** ***bias*** ***and*** ***influence*** ***analysis***

There was a symmetrical distribution in funnel plots of continuous variables (Figure4 A) and RRs (Figure 4 B). Because only two studies were used to perform meta-analysis of treatment effect, we recalculated overall SMD of CD8+ T cell count (*I*2 = 0, overall SMD = -3.59, 95%CI: -4.37--2.80, *P* = 0.737, Table 6), lesion volume (*I*2 = 0, overall SMD = -0.17, 95%CI: -0.75-0.42, *P* = 0.917, Table 6), and mBI scores (*I*2 = 10.6%, overall SMD = 2.43, 95%CI: 1.59-3.26, *P* = 0.290, Table 6) after the fixed-effects model was switched to a random-effects model. Pooled RRs and their 95%CIs of fever (*I*2 = 0, pooled RR = 0.93, 95%CI: 0.37-2.32, *P* = 0.723, Table 6), suspected lung infection (*I*2 = 0, pooled RR = 0.90, 95%CI: 0.33-2.43, *P* = 0.723, Table 6), and all adverse events occurring at least once (*I*2 = 0, pooled RR = 0.82, 95%CI: 0.36-1.87, *P* = 0.969, Table 6) were analyzed using the same method as above. In addition, for sensitivity analysis, the pooled effect of the remaining studies was recalculated after omitting the study with the highest quality because more than two studies were used to perform meta-analysis of treatment safety. We considered that the study might be assessed to have higher quality for its larger number of included patients in studies with the same assessment in Cochrane Collaboration’s Tool of Assessing Risk of Bias. Finally, after omitting the study with the highest quality, we recalculated pool RRs and their 95%CIs of fever (Zhu *et* *al*[17] omitted, *I*2 = 0, pooled RR = 0.78, 95%CI: 0.23-2.68, *P* = 0.723, Table 6), suspected lung infection (Zhu *et* *al*[17] omitted, *I*2 = 0, pooled RR = 0.78, 95%CI: 0.23-2.68, *P* = 0.723, Table 6), and all adverse events occurring at least once (*I*2 = 0, pooled RR = 0.84, 95%CI: 0.33-2.18, *P* = 0.969, Table 6).

**DISCUSSION**

There were many clinical application of fingolimod due to its original medicine indication of reducing the migration of lymphocytes to the central nervous system, such as Alzheimer's disease and Susac syndrome[21,22]. Although the mechanisms of action of fingolimod in the treatment of AIS or ICHmight be different, absorption of infarction lesion in AIS or hematoma in ICH both involved cytophagy *via* microglia in brain tissue or immunocyte in peripheral blood across injured brain-blood barrier[23,24]. Edema around lesion has probable results of microcirculation obstruction, injured brain-blood barrier, and inflammatory response caused by lymphocyte infiltration in stroke patients, which may strongly affect recovery of neurological function and prognosis due to its space occupying and toxic effect. Thus, fingolimod might reduce secondary damage after stroke *via* its pharmacological action. In our meta-analysis of RCTs, although we did not find that fingolimod could accelerate reduction of lesion volume (*I*2 = 0, overall SMD = -0.17, 95%CI: -0.75-0.42, *P* = 0.917, Figure 3) *via* reducing lymphocyte counts in peripheral blood (*I*2 = 0, overall SMD = -3.59, 95%CI: -4.37--2.80, *P* = 0.737, Figure 3), there was an effective improvement in ADL in stroke patients (*I*2 = 10.6%, overall SMD = 2.42, 95%CI: 1.63-3.21, *P* = 0.290, Figure 3), which might be the evidence that fingolimod might cause reduction of secondary damage *via* reducing lymphocyte infiltration in the brain effectively.

With regard to safety of oral fingolimod in stroke patients, infectious diseases might be the main adverse events. Especially, patients with hemiplegic paralysis may be aggravated to severe hypostatic pneumonia. In our meta-analysis, fever (*I*2 = 0, pooled RR = 0.93, 95%CI: 0.97-2.32, *P* = 0.864, Figure 4) and suspected lung infection (*I*2 = 0, pooled RR = 0.90, 95%CI: 0.33-2.43, *P* = 0.876, Figure 4) were both considered as infectious diseases. We did not find that fingolimod might increase the risk of infection. Regarding other adverse events, there were some rare severe adverse events in the fingolimod group. Risk of cerebral hernia was not increased after the medication (RR = 0.35, 95%CI: 0.06-1.90, Table 3). The reason might be the large lesion volume at baseline. In the clinical trial by Tian *et* *al*[18], fingolimod was applied based on delayed alteplase administration. Hemorrhage of the digestive tract is definitely the potential risk during thrombolytic therapy. However, we found that the risk of digestive tract hemorrhage was not increased in the fingolimod group (RR = 0.42, 95%CI: 0.04-4.30, Table 3). Sphingosine-1-phosphate can regulate calcium ion movement in cells, which can affect myocardial contractility[25]. Therefore, fingolimod-phosphate can bind to sphingosine-1-phosphate receptors, which might result in arhythmia, such as bradycardia and atrial flutter. Likewise, sphingosine-1-phosphate can be produced from platelets and participate in platelet activation, which might result in thrombocytopenia in the fingolimod group[26]. Therefore, the application of fingolimod should be cautious in patients with a history of cardiac disease and platelet disorder. In general, according to pooled RR of adverse events occurring at least once (*I*2 = 0, pooled RR = 0.82, 95%CI: 0.36-1.87, *P* = 0.995, Figure 4), fingolimod might be safe for stroke patients.

Only four RCTs were included in the meta-analysis finally. Furthermore, two of them were completed by the team led by the same professor. The studies included was insufficient to perform a meta-analysis with high quality due to an insufficient number of patients. Although publication bias was not found, the outcome might be influenced by tendentiousness of articles with the same first authors. As some results were only shown in figures in some articles, these results were not extracted, which may lead to missing data at other time points and some variables, such as counts of other types of lymphocytes, edema around lesion, and NIHSS scores. In addition, there was potential influence of non-original data because data of continuous variables used in meta-analysis were processed *via* mathematical transformation owing to statistical difference before meta-analysis. Although a few stroke patients used fingolimod as a therapeutic medication, we believe that our research would bring about a new direction of stroke medication.

**CONCLUSION**

Fingolimod might improve neurological function in stroke patients byreducing lymphocyte infiltration in the brain effectively; however, we did not find the evidence that it could promote infarction lesion or hematoma absorption. In general, oral fingolimod (0.5 mg/d, 3 consecutive days) is safe in stroke patients except for some rare severe adverse events.

**ARTICLE HIGHLIGHTS**

***Research*** ***background***

Brain tissue injury in stroke patients involves inflammation around the infarction lesion or hematoma, which is an important reason for disease deterioration and can result in a poor prognosis. The meta-analysis of animal experiments has concluded that fingolimod could treat stroke in animal models by effectively reducing lymphocyte infiltration.

***Research*** ***motivation***

The evidence-based of efficacy and safety evaluation of fingolimod in stroke patients is currently unavailable.

***Research*** ***objectives***

We hypothesized that fingolimod could effectively and safely promote reduction of infarction lesion or hematoma and improve neurological prognosis in AIS or ICH patients by reducing lymphocyte infiltration.

***Research*** ***methods***

In this study, we performed a systemic review and meta-analysis of recent randomized controlled trials to confirm the above hypothesis.

***Research*** ***results***

There was a significant difference in CD8+ T cell count and modified Barthel index between the fingolimod and control groups. However, there was no significant difference in lesion volume, fever, suspected lung infection (pooled RR = 0.90, 95%CI: 0.33-2.43, *P* = 0.876), and all adverse events occurring at least once between the fingolimod and control groups.

***Research*** ***conclusions***

Fingolimod might improve neurological function in stroke patients by reducing lymphocyte infiltration in the brain effectively. Fingolimod might not promote infarction lesion or hematoma absorption. Oral fingolimod (0.5 mg/d, 3 consecutive days) is safe in stroke patients except for some rare severe adverse events.

***Research*** ***perspectives***

More high-quality randomized controlled studies involving more patients are needed to provide more clinical research evidence.

**REFERENCES**

1 Trejo-Gabriel-Galán JM. Stroke as a complication and prognostic factor of COVID-19. Neurologia 2020; 35: 318-322. [PMID: PMC7200328 DOI: 10.1016/j.nrl.2020.04.015]

2 **Markus HS**, Brainin M. COVID-19 and stroke-A global World Stroke Organization perspective. *Int* *J* *Stroke* 2020; **15**: 361-364 [PMID: 32310017 DOI: 10.1177/1747493020923472]

3 **Droegemueller CJ**, Kashyap B, Huna Wagner RL, Shibeshi H, Clayton MW, Fennig MW, Hussein HM. A Successful Quality Improvement Project for Detection and Management of Acute Stroke in Hospitalized Patients. *J* *Neurosci* *Nurs* 2020; **52**: 186-191 [PMID: 32427652 DOI: 10.1097/JNN.0000000000000517]

4 **Huwiler A**, Zangemeister-Wittke U. The sphingosine 1-phosphate receptor modulator fingolimod as a therapeutic agent: Recent findings and new perspectives. *Pharmacol* *Ther* 2018; **185**: 34-49 [PMID: 29127024 DOI: 10.1016/j.pharmthera.2017.11.001]

5 **Mandal P**, Gupta A, Fusi-Rubiano W, Keane PA, Yang Y. Fingolimod: therapeutic mechanisms and ocular adverse effects. *Eye (Lond)* 2017; **31**: 232-240 [PMID: 27886183 DOI: 10.1038/eye.2016.258]

6 **Chitnis T**, Arnold DL, Banwell B, Brück W, Ghezzi A, Giovannoni G, Greenberg B, Krupp L, Rostásy K, Tardieu M, Waubant E, Wolinsky JS, Bar-Or A, Stites T, Chen Y, Putzki N, Merschhemke M, Gärtner J; PARADIGMS Study Group. Trial of Fingolimod *vs* Interferon Beta-1a in Pediatric Multiple Sclerosis. *N* *Engl* *J* *Med* 2018; **379**: 1017-1027 [PMID: 30207920 DOI: 10.1056/NEJMoa1800149]

7 **Wang Z**, Kawabori M, Houkin K. FTY720 (Fingolimod) Ameliorates Brain Injury through Multiple Mechanisms and is a Strong Candidate for Stroke Treatment. *Curr Med Chem* 2020; **27**: 2979-2993 [PMID: 31785606 DOI: 10.2174/0929867326666190308133732]

8 **Dang C**, Lu Y, Li Q, Wang C, Ma X. Efficacy of the sphingosine-1-phosphate receptor agonist fingolimod in animal models of stroke: an updated meta-analysis. *Int* *J* *Neurosci* 2021; **131**: 85-94 [PMID: 32148137 DOI: 10.1080/00207454.2020.1733556]

9 **Farr SA**, Cuzzocrea S, Esposito E, Campolo M, Niehoff ML, Doyle TM, Salvemini D. Adenosine A3 receptor as a novel therapeutic target to reduce secondary events and improve neurocognitive functions following traumatic brain injury. *J Neuroinflammation* 2020; **17**: 339 [PMID: 33183330 DOI: 10.1186/s12974-020-02009-7]

10 **Liu C**, Yang J, Zhang C, Geng X, Zhao H. Remote ischemic conditioning reduced cerebral ischemic injury by modulating inflammatory responses and ERK activity in type 2 diabetic mice. *Neurochem* *Int* 2020; **135**: 104690 [PMID: 31981607 DOI: 10.1016/j.neuint.2020.104690]

11 **Selim M**, Norton C. Perihematomal edema: Implications for intracerebral hemorrhage research and therapeutic advances. *J* *Neurosci* *Res* 2020; **98**: 212-218 [PMID: 30575082 DOI: 10.1002/jnr.24372]

12 **Anderson A**, Klein J, White B, Bourgeois M, Leonard A, Pacino A, Hill J, Lyden P. Training and Certifying Users of the National Institutes of Health Stroke Scale. *Stroke* 2020; **51**: 990-993 [PMID: 31986988 DOI: 10.1161/STROKEAHA.119.027234]

13 **Ohura T**, Hase K, Nakajima Y, Nakayama T. Validity and reliability of a performance evaluation tool based on the modified Barthel Index for stroke patients. *BMC* *Med* *Res* *Methodol* 2017; **17**: 131 [PMID: 28841846 DOI: 10.1186/s12874-017-0409-2]

14 **Huang D**, Yu H, Wang T, Yang H, Yao R, Liang Z. Efficacy and safety of umifenovir for coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis. *J* *Med* *Virol* 2021; **93**: 481-490 [PMID: 32617989 DOI: 10.1002/jmv.26256]

15 **Fu Y**, Zhang N, Ren L, Yan Y, Sun N, Li YJ, Han W, Xue R, Liu Q, Hao J, Yu C, Shi FD. Impact of an immune modulator fingolimod on acute ischemic stroke. *Proc* *Natl* *Acad* *Sci* *U* *S* *A* 2014; **111**: 18315-18320 [PMID: 25489101 DOI: 10.1073/pnas.1416166111]

16 **Fu Y**, Hao J, Zhang N, Ren L, Sun N, Li YJ, Yan Y, Huang D, Yu C, Shi FD. Fingolimod for the treatment of intracerebral hemorrhage: a 2-arm proof-of-concept study. *JAMA* *Neurol* 2014; **71**: 1092-1101 [PMID: 25003359 DOI: 10.1001/jamaneurol.2014.1065]

17 **Zhu Z**, Fu Y, Tian D, Sun N, Han W, Chang G, Dong Y, Xu X, Liu Q, Huang D, Shi FD. Combination of the Immune Modulator Fingolimod With Alteplase in Acute Ischemic Stroke: A Pilot Trial. *Circulation* 2015; **132**: 1104-1112 [PMID: 26202811 DOI: 10.1161/CIRCULATIONAHA.115.016371]

18 **Tian DC**, Shi K, Zhu Z, Yao J, Yang X, Su L, Zhang S, Zhang M, Gonzales RJ, Liu Q, Huang D, Waters MF, Sheth KN, Ducruet AF, Fu Y, Lou M, Shi FD. Fingolimod enhances the efficacy of delayed alteplase administration in acute ischemic stroke by promoting anterograde reperfusion and retrograde collateral flow. *Ann* *Neurol* 2018; **84**: 717-728 [PMID: 30295338 DOI: 10.1002/ana.25352]

19 **Li YJ**, Chang GQ, Liu Y, Gong Y, Yang C, Wood K, Shi FD, Fu Y, Yan Y. Fingolimod alters inflammatory mediators and vascular permeability in intracerebral hemorrhage. *Neurosci* *Bull* 2015; **31**: 755-762 [PMID: 25958190 DOI: 10.1007/s12264-015-1532-2]

20 **Liantao Z**, Jing Z, Lingling L, Hua L. Efficacy of fingolimod combined with alteplase in acute ischemic stroke and rehabilitation nursing. *Pak* *J* *Pharm* *Sci* 2019; **32**: 413-419 [PMID: 30852478]

21 **Angelopoulou E**, Piperi C. Beneficial Effects of Fingolimod in Alzheimer's Disease: Molecular Mechanisms and Therapeutic Potential. *Neuromolecular* *Med* 2019; **21**: 227-238 [PMID: 31313064 DOI: 10.1007/s12017-019-08558-2]

22 **Gross CC**, Meyer C, Bhatia U, Yshii L, Kleffner I, Bauer J, Tröscher AR, Schulte-Mecklenbeck A, Herich S, Schneider-Hohendorf T, Plate H, Kuhlmann T, Schwaninger M, Brück W, Pawlitzki M, Laplaud DA, Loussouarn D, Parratt J, Barnett M, Buckland ME, Hardy TA, Reddel SW, Ringelstein M, Dörr J, Wildemann B, Kraemer M, Lassmann H, Höftberger R, Beltrán E, Dornmair K, Schwab N, Klotz L, Meuth SG, Martin-Blondel G, Wiendl H, Liblau R. CD8+ T cell-mediated endotheliopathy is a targetable mechanism of neuro-inflammation in Susac syndrome. *Nat* *Commun* 2019; **10**: 5779 [PMID: 31852955 DOI: 10.1038/s41467-019-13593-5]

23 **Nishihara H**, Maeda T, Sano Y, Ueno M, Okamoto N, Takeshita Y, Shimizu F, Koga M, Kanda T. Fingolimod promotes blood-nerve barrier properties in vitro. *Brain* *Behav* 2018; **8**: e00924 [PMID: 29670818 DOI: 10.1002/brb3.924]

24 **Zhou YX**, Wang X, Tang D, Li Y, Jiao YF, Gan Y, Hu XM, Yang LQ, Yu WF, Stetler RA, Li PY, Wen DX. IL-2mAb reduces demyelination after focal cerebral ischemia by suppressing CD8+ T cells. *CNS* *Neurosci* *Ther* 2019; **25**: 532-543 [PMID: 30444079 DOI: 10.1111/cns.13084]

25 **Jozefczuk E**, Guzik TJ, Siedlinski M. Significance of sphingosine-1-phosphate in cardiovascular physiology and pathology. *Pharmacol* *Res* 2020; **156**: 104793 [PMID: 32278039 DOI: 10.1016/j.phrs.2020.104793]

26 **Vu TM**, Ishizu AN, Foo JC, Toh XR, Zhang F, Whee DM, Torta F, Cazenave-Gassiot A, Matsumura T, Kim S, Toh SES, Suda T, Silver DL, Wenk MR, Nguyen LN. Mfsd2b is essential for the sphingosine-1-phosphate export in erythrocytes and platelets. *Nature* 2017; **550**: 524-528 [PMID: 29045386 DOI: 10.1038/nature24053]

**Footnotes**

**Conflict-of-interest statement:** On behalf of all authors, the corresponding author states that there is no conflict of interest to disclose.

**PRISMA 2009 Checklist statement:** The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** August 18, 2021

**First decision:** November 2, 2021

**Article in press:** December 24, 2021

**Specialty type:** Clinical neurology

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): 0

Grade D (Fair): D, D

Grade E (Poor): 0

**P-Reviewer:** Cheungpasitporn W, Liu JM **S-Editor:** Liu M **L-Editor:** Wang TQ **P-Editor:** Liu M

**Figure Legends**



**Figure 1 Process of study screening.**

****

**Figure 2 Quality assessment for studies included.** 1-Ying Fu et al”[15] and 2-Ying Fu et al[16] represent two different references.



**Figure 3 Forest plots of overall standard mean difference and pooled risk ratio.** A: Overall standard mean difference of T-lymphocytes with cluster of differentiation 8 expression/infarction or hematoma volume/modified Barthel index scores; B: Pooled risk ratio of fever/suspected lung infection/adverse events occurring at least once. 1-Ying Fu et al”[15] and 2-Ying Fu et al[16] represent two different references. mBI scores: Modified Barthel index scores. RR: Risk ratio; CD8+ T cell: T-lymphocytes with cluster of differentiation 8 expression; Lesion volume: Infarction or hematoma volume; SMD: Standard mean difference.

****

**Figure 4 Funnel plots of publication bias.** A: Funnel plot of variables used to acquire overall standard mean difference; B: Funnel diagram of risk ratio.

**Table 1 Agreement of studies included by Zhao K and Guo Y**

|  |  |  |
| --- | --- | --- |
| **Zhao K** | **Guo Y** | **Total** |
| **+** | **-** |
| + | 4 | 3 | 7 |
| - | 2 | 176 | 179 |
| Total | 6 | 179 | 185 |

Kappa = 0.601, *P* < 0.001.

**Table 2 Characteristics of studies used to perform the meta-analysis**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Ref.** | **Publication** | **Fingolimod** **group**  | **Types of stroke** | **Age****(mean ± SD)** | **Sex****(male %)** | **Dose of fingolimod** | **Conclusion** |
| Fu *et al***[15]** | 2014 | 11 | AIS | 62.3 ± 8.0 | 73 | 0.5 mg/d orally, 3 consecutive days after hospitalization | It could safely limit secondary tissue injury, decrease microvascular permeability, attenuate neurological deficits, and promote recovery. |
| Fu *et al***[16]** | 2014 | 11 | ICH | 60.7 ± 12.3 | 36 | 0.5 mg/d orally, 3 consecutive days after hospitalization | It could safely reduce PHE, attenuate neurologic deficits, and promote recovery.  |
| Zhu *et al***[17]** | 2015 | 22 | AIS | 60.0 ± 2.5 | 59 | 0.5 mg/d orally, 3 consecutive days after hospitalization  | In this pilot study, combination therapy of fingolimod and alteplase was well tolerated, which attenuated reperfusion injury and improved clinical outcomes in AIS patients.  |
| Tian *et al***[18]** | 2018 | 23 | AIS | 67 ± 6.7 | 39 | 0.5 mg/d orally, 3 consecutive days after hospitalization | Fingolimod may enhance the efficacy of alteplase administration in the 4.5- to 6-h time window in patients with a proximal cerebral arterial occlusion and salvageable penumbral tissue by promoting both anterograde reperfusion and retrograde collateral flow. |

SD: Standard deviation.

**Table 3 Agreement of data extraction between Zhao K and Guo Y**

|  |  |  |
| --- | --- | --- |
| **Kai Zhao** | **Yu Guo** | **Total** |
| **+** | **-** |
| + | 16 | 5 | 21 |
| - | 3 | 20 | 23 |
| Total | 19 | 25 | 44 |

Kappa = 0.634, *P* < 0.001.

**Table 4 Changes of** **T-lymphocytes with cluster of differentiation 8 expression/****infarction or hematoma volume/****modified Barthel index scores in the fingolimod and control groups**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Ref.** | **Size of fingolimod group** | **Fingolimod group** | **Size of control group** | **Control group** |
| CD8+ T cell count (mean ± SD, × 106/mL)1 |  |  |  |  |
| Fu *et al*[15] | 11 | -0.16 ± 0.04 | 11 | 0.08 ± 0.08 |
| Tian *et al*[18] | 23 | -0.09 ± 0.02 | 23 | -0.02 ± 0.02 |
| Lesion Volume (mean ± SD, mL)2 |  |  |  |  |
| Fu *et al*[15] | 11 | 9.91 ± 79.62 | 11 | 25.45 ± 75.45 |
| Fu *et al*[16] | 11 | -1.97 ± 6.25 | 12 | -1.35 ± 1.77 |
| mBI score (mean ± SD)3 |  |  |  |  |
| Fu *et al*[15] | 11 | 72.7 ± 7.5 | 11 | 45.3 ± 10.9 |
| Fu *et al*[16] | 11 | 75.2 ± 4.7 | 12 | 65.4 ± 4.8 |

1The outcome equaled CD8+ T cell count at 1 d after taking fingolimod orally minus CD8+ T cell count at baseline.

2Lesion volume consisted of infarct volume of AIS and hematoma volume of ICH. The outcome is lesion volume at 7 d after taking fingolimod orally minus lesion volume at baseline.

3The outcome is mBI score at 90 days after fingolimod taken orally minus mBI score at baseline.

CD8+ T cell: T-lymphocytes with cluster of differentiation 8 expression. Lesion volume: Infarction or hematoma volume; mBI score: Modified Barthel index score.

**Table 5 Complications and adverse events in the fingolimod and control groups**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Ref.** | **Size of fingolimod group** | **Events of fingolimod group** | **Size of control group** | **Events of control group** | **Risk ratio (95%CI)** |
| Fever |  |  |  |  |  |
| Fu *et al*[15] | 11 | 3 | 11 | 3 | 1 (0.16, 6.08) |
| Fu *et al*[16] | 11 | 3 | 12 | 5 | 0.64 (0.12, 3.34) |
| Zhu *et al*[17] | 22 | 5 | 25 | 5 | 1.15 (0.29, 4.51) |
| Suspected lung infection |  |  |  |  |  |
| Fu *et al*[15] | 11 | 3 | 11 | 3 | 1 (0.16, 6.08) |
| Fu *et al*[16] | 11 | 3 | 12 | 5 | 0.64 (0.12, 3.34) |
| Zhu *et al*[17] | 22 | 3 | 25 | 3 | 1.17 (0.21, 6.39) |
| Adverse events occurring at least once |  |  |  |  |  |
| Fu *et al*[15] | 11 | 3 | 11 | 3 | 1 (0.16, 6.08) |
| Fu *et al*[16] | 11 | 4 | 12 | 6 | 0.72 (0.12, 4.38) |
| Zhu *et al*[17] | 22 | 6 | 25 | 8 | 0.84 (0.25, 2.81) |
| Tian *et al*[18] | 23 | 3 | 23 | 4 | 0.76 (0.15, 3.81) |
| Other serious events |  |  |  |  |  |
| Hemorrhage of digestive tract |  |  |  |  |  |
| Zhu *et al*[17] | 22 | 1 | 25 | 3 | 0.42 (0.04, 4.30) |
| Cerebral hernia |  |  |  |  |  |
| Tian *et al*[18] | 23 | 2 | 23 | 6 | 0.35 (0.06, 1.90) |
| Bradycardia |  |  |  |  |  |
| Fu *et al*[16] | 11 | 1 | 12 | 0 | N/A |
| Atrial flutter |  |  |  |  |  |
| Tian *et al*[18] | 23 | 2 | 23 | 0 | N/A |
| Thrombocytopenia |  |  |  |  |  |
| Tian *et al*[18] | 23 | 2 | 23 | 0 | N/A |

**Table 6 Overall** **standard** **mean difference or pooled** **risk ratio *via* random-effects model and pooled risk ratio of remaining studies after the study with the highest quality is omitted**

|  |  |  |
| --- | --- | --- |
| **Method** | **Overall SMD or RR (95%CI)** | **Test of heterogeneity** |
| ***I*2 (%)** | ***P*** |
| Random-effects model |  |  |  |
| CD8+ T cells | -3.59 (-4.37, -2.80) | 0.0 | 0.737 |
| Lesion volume | -0.17 (-0.75, 0.42) | 0.0 | 0.917 |
| mBI score | 2.43 (1.59, 3.26) | 10.6 | 0.290 |
| RR of fever | 0.93 (0.37, 2.32) | 0.0 | 0.864 |
| RR of suspected lung infection | 0.90 (0.33, 2.43) | 0.0 | 0.876 |
| RR of adverse events occurring at least once | 0.82 (0.36, 1.87) | 0.0 | 0.995 |
| Article deleted |  |  |  |
| Zhu *et al*[17] (RR of fever) | 0.78 (0.23, 2.68) | 0.0 | 0.723 |
| Zhu *et al*[17] (RR of suspected lung infection) | 0.78 (0.23, 2.68) | 0.0 | 0.723 |
| Tian *et al*[18] (RR of adverse events occurring at least once) | 0.84 (0.33, 2.18) | 0.0 | 0.969 |

SMD: Standard mean difference; RR: Risk ratio; CD8+ T cell: T-lymphocytes with cluster of differentiation 8 expression; Lesion volume: Infarction or hematoma volume; mBI score: Modified Barthel index score.



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2021 Baishideng Publishing Group Inc. All rights reserved.**